Document:

exv10w1

Exhibit 10.1

FIRST AMENDMENT TO

ASSET PURCHASE AGREEMENT

          THIS FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this “First Amendment”), dated as of
August 8, 2008, is by and between American Medical Systems, Inc., a Delaware corporation
(“Purchaser”), and Bio Control Medical (B.C.M), Ltd., an Israeli corporation
(“Seller”).

          WHEREAS, Purchaser and Seller entered into an Asset Purchase Agreement, dated as of April 26,
2006 (the “Purchase Agreement”);

          WHEREAS, Section 8.2 of the Purchase Agreement permits the parties to amend the terms thereof
by the written agreement of all the parties thereto;

          WHEREAS, Purchaser and Seller entered into an Amended and Restated License Agreement effective
January 1, 2008 (the “Amended License Agreement”);

          WHEREAS, the First Amendment to the Amended License Agreement (the “License
Amendment”) is also being executed in connection with this First Amendment;

          WHERAS, the Second Milestone has been met and Purchaser has paid the Second Milestone Payment
to Seller; and

          WHEREAS, the parties desire to amend portions of the Purchase Agreement as set forth herein.

          ACCORDINGLY, the parties hereby agree as follows:

	1.	 	First Milestone Satisfied. Purchaser is hereby deemed to have satisfied the First
Milestone pursuant to the terms of Section 1.5(a) of the Purchase Agreement, and Purchaser
shall pay Seller the entire First Milestone Payment of $7,500,000. Payment of such amount
will be made by Purchaser to Seller on or before September 30, 2008 (notwithstanding the
payment provisions of Section 1.5 of the Purchase Agreement).
	 
	2.	 	Amendment to Section 4.7. Section 4.7 of the Purchase Agreement is hereby eliminated
in its entirety and, notwithstanding anything to the contrary in this Amendment, the Purchase
Agreement, the Ancillary Agreements or any other agreements between Purchaser and Seller,
Seller acknowledges and agrees that (i) Purchaser has no express or implied obligation
whatsoever to meet or attempt to meet the Third Milestone, and (ii) Purchaser may, in its sole
and absolute discretion, elect to pursue other opportunities or businesses and abandon or
terminate any activities that may help meet the Third Milestone (in whole or in part) at any
time or decline any one or more opportunities related to meeting the Third Milestone, in each
case for any reason or for no reason and without any liability or responsibility to Seller.
	 
	3.	 	Waiver, Release and Covenant not to Sue. Notwithstanding anything to the contrary in
this Amendment, the Purchase Agreement, the Ancillary Agreements or any other agreements
between Purchaser and Seller, and in consideration for the Seller agreeing

 

 

	 	 	that the First Milestone is met and paying the First Milestone Payment to Buyer, Seller
hereby waives all rights it had or may have had and hereby discharges and forever releases
Purchaser (including each of its former, current or future affiliates, parents,
subsidiaries, directors, officers, shareholders, employees, agents, constituents, clients,
attorneys, insurers, predecessors, successors, and assigns) from any and all claims,
demands, damages and/or causes of action of any nature or description whatsoever, known or
unknown, liquidated or unliquidated, that it may have had, now has, or may in the future
have based on past, present or further conduct, action or inaction on the part of Purchaser
and arising out of or in any way related to Purchaser’s efforts to achieve the Milestones
(“Claims”); provided, however, that, subject to AMS’s rights under Section 2(a) of
the License Amendment, the foregoing release shall not cover any Claims that relate to the
failure to pay royalties that become due from AMS on future sales of Licensed Products under
the Amended License Agreement, as amended by the License Amendment. Seller further
covenants and expressly agrees not to prosecute or participate in any suit, action, cause of
action or proceeding related to Claims of any kind against Purchaser or any of its former,
current or future affiliates, parents, subsidiaries, directors, officers, shareholders,
employees, agents, constituents, clients, attorneys, insurers, predecessors, successors, and
assigns.”
	 
	4.	 	Additional Agreements Relating to Third Milestone. Subject in all cases to Sections
2 and 3 of this Amendment, Seller and Purchaser agree as follows:

	 	(a)	 	If and when the Third Milestone is achieved by Purchaser, Purchaser shall
remain liable for the Third Milestone Payment pursuant to the terms of Section 1.5(c)
of the Purchase Agreement.
	 
	 	(b)	 	If, prior to the Purchaser’s achievement of the Third Milestone, Purchaser
(i) sells or otherwise transfers all or substantially all of the Purchased Assets to
one or more non-affiliated third parties, or (ii) grants sublicenses under the Amended
License Agreement, as amended, to one or more non-affiliated third parties and
receives consideration therefor in addition to or other than royalties subject to
Section 3(b) thereof (each a “Transfer”), then Purchaser will pay to Seller
twenty-five percent (25%) of any payment(s) it receives from the Transfer, excluding
royalties subject to sub-license royalties under Section 3(b) of the Amended License
Agreement.
	 
	 	(c)	 	Purchaser’s maximum, aggregate liability to Seller related to achievement of
the Third Milestone and in connection with any Transfer(s), pursuant to clause (b),
above, shall be the original Third Milestone Payment amount of $10,000,000.
	 
	 	(d)	 	For the avoidance of doubt, Seller acknowledges and agrees that: (i) one or
more Transfers may have the effect of eliminating any and all possibility of Purchaser
achieving the Third Milestone; (ii) any obligation to make the Third Milestone Payment
is solely an obligation of the Purchaser, contingent upon Purchaser’s achievement of
the Third Milestone, and neither Purchaser nor any third party transferee will have any
liability to Seller under circumstances whereby such third

2

 

	 	 	 	party transferee shall have achieved the goals specified in for the Third Milestone;
and (iii) Seller may never realize the maximum amount under clause (c) above.
	 
	 	(e)	 	Seller agrees to cooperate, in good faith, in connection with any Transfer, and
agrees that any required consents of Seller for any Transfer will not be unreasonably
withheld.

	5.	 	Execution of License Amendment. Each party shall execute the License Amendment on
the date they execute this First Amendment.
	 
	6.	 	Defined Terms. Capitalized words that are not defined herein shall have the meaning
given to them in the Purchase Agreement.
	 
	7.	 	No Other Amendments. Except as amended herein, the Purchase Agreement shall remain
in full force and effect in accordance with its original terms.
	 
	8.	 	Counterparts. This First Amendment may be signed in any number of counterparts and
the signatures delivered by facsimile, each of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument.
	 
	9.	 	Governing Law. This Amendment shall be construed and enforced in accordance with the
laws of the State of New York.

(Signature Page Follows)

3

 

     IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be duly executed by
their respective authorized officers as of the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	AMERICAN MEDICAL SYSTEMS, INC.	 	 	 	BIO CONTROL MEDICAL (B.C.M), LTD.	 	 
	a Delaware corporation	 	 	 	an Israeli corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Anthony P. Bihl, III
 

Anthony P. Bihl, III
	 	 	 	By:

Name:
	 	/s/ Ehud Cohen, Ph.D.
 

Ehud Cohen, Ph.D.
	 	 
	Title:

	 	CEO – 8/13/08
	 	 	 	Title:
	 	CEO	 	 

(Signature Page to First Amendment to Asset Purchase Agreement)

4exv10w2

Exhibit 10.2

FIRST AMENDMENT TO

AMENDED AND RESTATED LICENSE AGREEMENT

     THIS FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT (this “First
Amendment”), dated as of August 8, 2008, is by and between American Medical Systems, Inc., a
Delaware corporation (“AMS”), and Bio Control Medical (B.C.M), Ltd., an Israeli corporation
(“Bio Control”).

     WHEREAS, AMS and Bio Control entered into an Amended and Restated License Agreement, dated as
of January 1, 2008 (the “Existing License Agreement”), which amended and restated the
original License Agreement by and between AMS and Bio Control dated April 26, 2006;

     WHEREAS, Section 9(e) of the Existing License Agreement permits the parties to amend the terms
thereof by the written agreement of AMS and Bio Control;

     WHEREAS, the First Amendment to Asset Purchase Agreement between AMS and Bio Control (the
“Purchase Agreement Amendment”) is also being executed in connection with this First
Amendment; and

     WHEREAS, the parties desire to amend portions of the Existing License Agreement as set forth
herein.

     ACCORDINGLY, the parties hereby agree as follows:

	1.	 	Amendment to Section 3(a). Section 3(a) of the Existing License Agreement is hereby
amended in its entirety as follows:

     “(a) Percentage Royalty. Commencing on April 26, 2006, and for a
period of thirteen (13) years thereafter or, if earlier, upon the expiration or
termination of this Agreement, AMS shall pay to Bio Control, or its designee, a
royalty equal to the percentage of Net Sales set forth below during each fiscal year
of AMS occurring within the periods set forth below (subject to appropriate
adjustment for any subsequent change in AMS’ fiscal year

	 	 	 	 	 
	      Fiscal Period	 	Royalty Rate
	2006 through 2009
	 	 	6	%
	2010 through 2012
	 	 	5	%
	2013 through 2019
	 	 	4	%

     All royalty payments hereunder will be reduced by the amount of any tax withholdings
required to be withheld by AMS under applicable tax laws and regulations as in effect from
time to time.”

 

 

	2.	 	Sales of Licensed Products; Waiver, Release and Covenant not to Sue. Notwithstanding
anything to the contrary herein, in the Existing License Agreement or any other agreements
between AMS and Bio Control, and in consideration for the extension of the royalty period
provided in Section 1 of this First Amendment, Bio Control agrees as follows:

     (a) Bio Control acknowledges and agrees that (i) AMS has no express or implied
obligation to generate sales of Licensed Products whatsoever, and (ii) AMS may, in its sole
and absolute discretion, elect to pursue other opportunities or businesses and abandon or
terminate any activities that otherwise may help generate sales of Licensed Products and
earn royalties thereon, at any time or decline any one or more opportunities related to
generating sales of the Licensed Products and royalties, in each case for any reason or for
no reason and without any liability or responsibility to Bio Control.

     (b) Bio Control hereby waives all rights it had or may have had and hereby discharges
and forever releases AMS (including each of its former, current or future affiliates,
parents, subsidiaries, directors, officers, shareholders, employees, agents, constituents,
clients, attorneys, insurers, predecessors, successors, and assigns) from any and all
claims, demands, damages and/or causes of action of any nature or description whatsoever,
known or unknown, liquidated or unliquidated, that it may have had, now has, or may in the
future have based on past, present or further conduct, action or inaction on the part of AMS
and arising out of or in any way related to sales of Licensed Products or the generation of,
or failure to generate any, royalty payments under the License Agreement (“Claims”);
provided, however, that, subject to AMS’s rights under Section 2(a) hereof, the foregoing
release shall not cover any Claims that relate to the failure to pay royalties that become
due from AMS on future sales of Licensed Products under the Existing License Agreement, as
amended hereby. Bio Control further covenants and expressly agrees not to prosecute or
participate in any suit, action, cause of action or proceeding related to Claims of any kind
against AMS or any of its former, current or future affiliates, parents, subsidiaries,
directors, officers, shareholders, employees, agents, constituents, clients, attorneys,
insurers, predecessors, successors, and assigns..

	3.	 	Execution of Purchase Agreement Amendment. Each party shall execute the Purchase
Agreement Amendment on the date they execute this First Amendment.

	4.	 	Defined Terms. Capitalized words that are not defined herein shall have the meaning
given to them in the Existing License Agreement.

	5.	 	No Other Amendments. Except as amended herein, the Existing License Agreement shall
remain in full force and effect in accordance with its original terms.

	6.	 	Counterparts. This First Amendment may be signed in any number of counterparts and
the signatures delivered by facsimile, each of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument.

	7.	 	Governing Law. This First Amendment shall be construed and enforced in accordance
with the laws of the State of New York.

2

 

     IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be duly executed by
their respective authorized officers as of the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	AMERICAN MEDICAL SYSTEMS, INC.	 	 	 	BIO CONTROL MEDICAL (B.C.M), LTD.	 	 
	a Delaware corporation	 	 	 	an Israeli corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Anthony P. Bihl, III
 

Anthony P. Bihl, III
	 	 	 	By:

Name:
	 	/s/ Ehud Cohen, Ph.D.
 

Ehud Cohen, Ph.D.
	 	 
	Title:

	 	CEO – 8/13/08
	 	 	 	Title:
	 	CEO	 	 

(Signature Page to First Amendment to Amended and Restated License Agreement)

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]